AdvanCell
Develops lead-212 targeted alpha therapies to treat cancer
$315MSeries D
Role not disclosedLoading investors…
Activity from announced rounds
Develops lead-212 targeted alpha therapies to treat cancer
Develops AI-designed CAR T therapies for solid tumors using spatial biology